Chi Hoon Maeng
Overview
Explore the profile of Chi Hoon Maeng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maeng C, Hui D, Kang J, Kim S, Kwon J
BMJ Open
. 2024 Dec;
14(12):e084829.
PMID: 39719281
Introduction: Chronic pain is one of the most common and serious symptoms of cancer. Despite the limitations of dose titration using only one type of opioid, the effects of opioid...
2.
Maeng C, Kim B, Ahn M, Choi I, Zang D, Kim B, et al.
Cancer Res Treat
. 2024 Oct;
PMID: 39438000
Purpose: This study evaluates the prognostic significance of tumor size at disease progression (PD) and depth of response (DOR) in cancer patients. Materials And Methods: We performed post hoc analysis...
3.
Kim H, Jung Y, Lee J, Lee H, Maeng C, Baek S, et al.
Medicine (Baltimore)
. 2024 Aug;
103(31):e39166.
PMID: 39093750
Rationale: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by an antibody that inhibits coagulation factor VIII activity. More than half of patients with AHA cannot identify underlying...
4.
Kim B, Maeng C, Keam B, Im Y, Ro J, Jung K, et al.
Cancer Res Treat
. 2024 Jul;
57(1):39-46.
PMID: 38993093
Purpose: The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to...
5.
Park K, Jung Y, Lee H, Kim H, Maeng C, Baek S, et al.
Sci Rep
. 2024 Jul;
14(1):15622.
PMID: 38972913
Despite the improved outcomes in patients with hematological malignancies, infections caused by multidrug-resistant organisms (MDROs) pose a new threat to these patients. We retrospectively reviewed the patients with hematological cancer...
6.
Maeng C, Kim H, Kim M
Ther Adv Med Oncol
. 2024 Apr;
16:17588359241241972.
PMID: 38559613
Background: Adjuvant chemotherapy can reduce recurrence rates by eradicating microscopic metastases which may persist after curative resection. However, the optimal time interval (TI) between the surgery and chemotherapy remains controversial....
7.
Lim S, Lee K, Kim J, Im H, Kim I, Han H, et al.
BMC Cancer
. 2024 Feb;
24(1):252.
PMID: 38395832
Background: Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable or metastatic advanced gastric cancer...
8.
Maeng C, Kim H, Kim M
Sci Rep
. 2023 Oct;
13(1):17154.
PMID: 37821636
Although both capecitabine plus oxaliplatin (CAPOX) and S-1 are accepted as adjuvant chemotherapy following gastrectomy for gastric cancer, the better option between the two is still controversial. We conducted a...
9.
Kim D, Lee H, Yu S, Kwon J, Ahn H, Kim J, et al.
J Hosp Palliat Care
. 2023 Sep;
24(4):204-213.
PMID: 37674642
Purpose: At the end of life, communication is a key factor for good care. However, in clinical practice, it is difficult to adequately discuss end-of-life care. In order to understand...
10.